Connectez-vous/S’inscrire
Votre e-mail a été envoyé.
GBI Biomanufacturing HQ 1850 NW 69th Ave Industriel/Logistique 3 522 m² À vendre Plantation, FL 33313 8 853 046 € (2 513,61 €/m²) Taux de capitalisation 6 %
Certaines informations ont été traduites automatiquement.
Informations principales sur l'investissement
- TRIPLE-NET LEASE – SEVEN YEARS REMAINING: 100% leased to GBI Biomanufacturing through May 2033 with minimal landlord responsibilities.
- NEW FLORIDA STEM CELL LEGISLATION: Recent state law enabling regenerative treatments supports increased demand for stem cell manufacturing capacity.
- STRATEGIC BROWARD COUNTY LOCATION: Access to Sunrise Boulevard, Interstate 95, Florida’s Turnpike, and Ft. Lauderdale-Hollywood International Airport.
- VALUE-ADD OPPORTUNITY: Value-Add Opportunity - 9.84% Pro Forma Cap Rate.
- LIFE SCIENCES MANUFACTURING FACILITY: Specialized laboratory and biologics production infrastructure designed for pharmaceutical-grade operations.
- MARK-TO-MARKET OPPORTUNITY: Tenant currently pays below-market rent of $16.20/SF, compared to an estimated current market rent of $24.00/SF.
Résumé analytique
GBI Biomanufacturing Headquarters, located at 1850 NW 69th Avenue in Plantation, Florida, a 38,000 square-foot biologics manufacturing and life sciences facility in Broward County. The property is fully leased to GBI Biomanufacturing, Inc., a contract development and manufacturing organization (CDMO) specializing in mammalian cell culture development and cGMP biologics production.
The asset is secured by a triple-net lease with approximately seven years of remaining term through May 31, 2033, providing stable cash flow while minimizing landlord responsibilities, as the tenant is responsible for taxes, insurance, operating expenses, and maintenance. The lease also includes 2.6 percent annual rent escalations, providing consistent income growth throughout the remaining primary lease term.
The facility supports highly specialized biologics manufacturing operations requiring tailored laboratory buildouts, advanced mechanical systems, and pharmaceutical-grade production infrastructure. GBI has invested approximately $26 million into the facility, demonstrating significant tenant commitment while creating substantial barriers to relocation.
The investment also offers a clear value-add component through the lease renewal structure. Upon the first renewal option, rent resets to 90 percent of prevailing market rent, representing over 40 percent mark-to-market rent upside based on current underwriting. This structure provides the ability to significantly increase income at the end of the primary term, producing a projected 9.84 percent cap rate in year seven.
Additionally, the property benefits from Florida’s recently enacted stem cell legislation, which allows certain regenerative treatments to be offered within the state and has helped increase demand for stem cell manufacturing capacity. GBI has indicated the expanded facility will support the production of up to one million stem cell units annually, positioning the asset within a rapidly growing segment of the biotechnology sector.
The asset is secured by a triple-net lease with approximately seven years of remaining term through May 31, 2033, providing stable cash flow while minimizing landlord responsibilities, as the tenant is responsible for taxes, insurance, operating expenses, and maintenance. The lease also includes 2.6 percent annual rent escalations, providing consistent income growth throughout the remaining primary lease term.
The facility supports highly specialized biologics manufacturing operations requiring tailored laboratory buildouts, advanced mechanical systems, and pharmaceutical-grade production infrastructure. GBI has invested approximately $26 million into the facility, demonstrating significant tenant commitment while creating substantial barriers to relocation.
The investment also offers a clear value-add component through the lease renewal structure. Upon the first renewal option, rent resets to 90 percent of prevailing market rent, representing over 40 percent mark-to-market rent upside based on current underwriting. This structure provides the ability to significantly increase income at the end of the primary term, producing a projected 9.84 percent cap rate in year seven.
Additionally, the property benefits from Florida’s recently enacted stem cell legislation, which allows certain regenerative treatments to be offered within the state and has helped increase demand for stem cell manufacturing capacity. GBI has indicated the expanded facility will support the production of up to one million stem cell units annually, positioning the asset within a rapidly growing segment of the biotechnology sector.
Informations sur l’immeuble
| Prix | 8 853 046 € | Surface du lot | 0,93 ha |
| Prix par m² | 2 513,61 € | Surface utile brute | 3 522 m² |
| Type de vente | Investissement triple net | Nb d’étages | 1 |
| Taux de capitalisation | 6 % | Année de construction/rénovation | 1980/2023 |
| Type de bien | Industriel/Logistique | Occupation | Mono |
| Sous-type de bien | Entrepôt | Ratio de stationnement | 0,29/1 000 m² |
| Classe d’immeuble | B | Nb d’accès plain-pied/portes niveau du sol | 1 |
| Zonage | I-LP, Plantation | ||
| Prix | 8 853 046 € |
| Prix par m² | 2 513,61 € |
| Type de vente | Investissement triple net |
| Taux de capitalisation | 6 % |
| Type de bien | Industriel/Logistique |
| Sous-type de bien | Entrepôt |
| Classe d’immeuble | B |
| Surface du lot | 0,93 ha |
| Surface utile brute | 3 522 m² |
| Nb d’étages | 1 |
| Année de construction/rénovation | 1980/2023 |
| Occupation | Mono |
| Ratio de stationnement | 0,29/1 000 m² |
| Nb d’accès plain-pied/portes niveau du sol | 1 |
| Zonage | I-LP, Plantation |
Caractéristiques
- Ligne d’autobus
Principaux occupants Cliquez ici pour accéder à
- Occupant
- Secteur d’activité
- m² Occupés
- Loyer/m²
- Type de bail
- Fin du bail
-
- Services professionnels, scientifiques et techniques
-
99,999 SF
- -
-
Lorem Ipsum
-
Jan 0000
Goodwin Biotechnology offers you a Single Source Solution™ with a full range of mammalian cell culture development and manufacturing services ranging from the creation of up and downstream processes sufficient for the manufacturing of proof of concept or toxicology product material to processes for licensed manufacturing.
| Occupant | Secteur d’activité | m² Occupés | Loyer/m² | Type de bail | Fin du bail | |
|
|
Services professionnels, scientifiques et techniques | 99,999 SF | - | Lorem Ipsum | Jan 0000 |
1 1
Fairly walkable
50/100
Very drivable
80/100
Limited public transit
30/100
Fairly bikeable
40/100
Taxes foncières
| Numéro de parcelle | 49-41-34-41-0090 | Évaluation des aménagements | 5 162 870 € |
| Évaluation du terrain | 1 040 000 € | Évaluation totale | 6 202 870 € |
Taxes foncières
Numéro de parcelle
49-41-34-41-0090
Évaluation du terrain
1 040 000 €
Évaluation des aménagements
5 162 870 €
Évaluation totale
6 202 870 €
1 sur 10
Vidéos
Visite extérieure 3D Matterport
Visite 3D
Photos
Street view
Rue
Carte
1 sur 1
Présenté par
GBI Biomanufacturing HQ | 1850 NW 69th Ave
Vous êtes déjà membre ? Connectez-vous
Hum, une erreur s’est produite lors de l’envoi de votre message. Veuillez réessayer.
Merci ! Votre message a été envoyé.